峯岹科技(688279.SH):擬2800萬元認購華科致芯9.06%的財產份額
格隆匯4月1日丨峯岹科技(688279.SH)公佈,為藉助專業投資機構的經驗和資源,拓寬投資方式和渠道,把握公司所在行業相關創新應用領域的投資機會,優化公司投資結構,公司擬作為有限合夥人,以自有資金出資人民幣2,800萬元認購華科致芯9.06%的財產份額。具體情況以最終簽署的《合夥協議》等法律文件為準。
其主要從事半導體產業及工業、汽車、新能源、高科技及電子等半導體產業鏈上下游相關領域投資,與公司主營業務集成電路研發和設計具有協同性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.